{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:05Z","timestamp":1791919625155,"version":"4.3.4"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"19","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Hepatocellular carcinoma (HCC) is rapidly spreading around the world with a high mortality\nrate. In the low- and middle-income nations most impacted by HCV and HBV infections, HCC\nplaces a significant strain on the healthcare system and leaches productive capability. An extensive\nstudy on HCC to create novel therapeutic approaches was motivated by the lack of adequate preventive\nor curative therapy methods. Several medications have been put forward and some drug molecules\nare under investigation by the Food and Drug Administration (FDA) for the treatment of HCC.\nHowever, these therapeutic choices fall short of the ideal due to toxicity and the rapid rise in drug\nresistance which decreases the efficacy of these therapeutics and leads to the severity of hepatocellular\ncarcinoma. Therefore, concerning these problems, there is a critical need for novel systemic combination\ntherapies as well as novel molecular entities that target various signalling pathways, reducing\nthe likelihood that cancer cells may develop treatment resistance. In this review, we discuss the\nconclusions of several studies suggesting that the N-heterocyclic ring system is a key structural component\nof many synthetic drugs with a diverse range of biological activities. Following nuclei, such\nas pyridazine, pyridine, and pyrimidines, along with benzimidazole, indole, acridine, oxadiazole,\nimidazole, isoxazole, pyrazole, quinolines, and quinazolines, have been included to provide a general\noverview of the link between structure and activity between heterocyclics and their derivatives\nagainst hepatocellular carcinoma. A comprehensive investigation of the structure-activity relationship\nbetween the series may be done by the direct comparison of anticancer activities with the reference.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557523666230508160924","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:10:32Z","timestamp":1683609032000},"page":"1871-1892","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Structural Insights into N-heterocyclic Moieties as an Anticancer Agent\nagainst Hepatocellular Carcinoma: An Exhaustive Perspective"],"prefix":"10.2174","volume":"23","author":[{"given":"Nikhil Kumar","family":"Chourasiya","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Integrated Drug Discovery Research Laboratory, Dr. Harisingh Gour University\n(A Central University), Sagar (MP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdous","family":"Fatima","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Integrated Drug Discovery Research Laboratory, Dr. Harisingh Gour University\n(A Central University), Sagar (MP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitali","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Integrated Drug Discovery Research Laboratory, Dr. Harisingh Gour University\n(A Central University), Sagar (MP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Kori","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Integrated Drug Discovery Research Laboratory, Dr. Harisingh Gour University\n(A Central University), Sagar (MP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnesh","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Dr. Harisingh Gour University (A Central\nUniversity), Sagar (MP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Kashaw","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Sagar Institute of Pharmaceutical Sciences,\nSagar (M.P.), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Use\u2010inspired Biomaterials &amp; Integrated Nano Delivery\n(U\u2010BiND) Systems Laboratory, Wayne State University, Detroit MI 48202, Michigan, USA"},{"name":"Molecular Imaging Program,\nKarmanos Cancer Institute, Detroit MI48201, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Kumar","family":"Kashaw","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Integrated Drug Discovery Research Laboratory, Dr. Harisingh Gour University\n(A Central University), Sagar (MP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"Galle P.R.","year":"2018","unstructured":"Galle P.R.; Forner A.; Llovet J.M.; Mazzaferro V.; Piscaglia F.; Raoul J-L.; Schirmacher P.; Vilgrain V.; EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2018,69(1),182-236","journal-title":"J Hepatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","volume":"7","author":"Yang J.D.","year":"2010","unstructured":"Yang J.D.; Roberts L.R.; Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010,7(8),448-458","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/17474124.2019.1568870","volume":"13","author":"Zhao J.","year":"2019","unstructured":"Zhao J.; Gray S.G.; Greene C.M.; Lawless M.W.; Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer. Expert Rev Gastroenterol Hepatol 2019,13(3),247-256","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=4","year":"2018","unstructured":"2018 https:\/\/gco.iarc.fr\/today\/onlineanalysismap?v=2020and#x0026;mode=populationand#x0026;mode_population=continentsand#x0026;population=900and#x0026;populations=900and#x0026;key=asrand#x0026;sex=0and#x0026;cancer=11and#x0026;type=0and#x0026;statistic=5and#x0026;prevalence=0and#x0026;population_group=0and#x0026;ages_group%5B%5D=0and#x0026;ages_group%5B%5D=17and#x0026;nb_items=10and#x0026;group_cancer=1and#x0026;include_nmsc=0and#x0026;include_nmsc_other=0and#x0026;projection=naturalearthand#x0026;color_palette=defaultand#x0026;map_scale=quantileand#x0026;map_nb_colors=5and#x0026;continent=0and#x0026;show_ranking=0and#x0026;rotate=%255B10%252C0%255D"},{"key":"ref=5","first-page":"327","author":"LaFemina J.","year":"2019","unstructured":"LaFemina J.; Switzer B.;  Whalen, GF Liver cancer: Hepatocellular carcinoma 2019,327-343","journal-title":"Whalen, GF Liver cancer: Hepatocellular carcinoma"},{"key":"ref=6","author":"Choi K.J.","year":"2015","unstructured":"Choi K.J.; Baik I.H.; Ye S.K.; Lee Y.H.;  2015"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1021\/ja0394434","volume":"126","author":"Dogan Z.","year":"2004","unstructured":"Dogan Z.; Paulini R.; Rojas St\u00fctz J.A.; Narayanan S.; Richert C.; 5\u2032-Tethered stilbene derivatives as fidelity- and affinity-enhancing modulators of DNA duplex stability. J Am Chem Soc 2004,126(15),4762-4763","journal-title":"J Am Chem Soc"},{"key":"ref=8","author":"Koulouris A.","year":"2021","unstructured":"Koulouris A.; Sagkaris C.T.; Spyrou V.; Pappa E.; Troullinou A.;  2021"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/co500125n","volume":"17","author":"Yang D.","year":"2015","unstructured":"Yang D.; An B.; Wei W.; Tian L.; Huang B.; Wang H.; Copper-catalyzed domino synthesis of nitrogen heterocycle-fused benzoimidazole and 1,2,4-benzothiadiazine 1,1-dioxide derivatives. ACS Comb Sci 2015,17(2),113-119","journal-title":"ACS Comb Sci"},{"key":"ref=10","first-page":"36","volume":"12","author":"Kim S.","year":"2014","unstructured":"Kim S.; Abou-Alfa G.K.; The role of tyrosine kinase inhibitors in hepatocellular carcinoma. Clin Adv Hematol Oncol 2014,12(1),36-41","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"Llovet J.M.","year":"2008","unstructured":"Llovet J.M.; Sergio R.; Vincenzo M.; Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008,359(4),378-390","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"Arora A.","year":"2005","unstructured":"Arora A.; Scholar E.M.; Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005,315(3),971-979","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"Hartmann J.","year":"2009","unstructured":"Hartmann J.; Haap M.; Kopp H.G.; Lipp H.P.; Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009,10(5),470-481","journal-title":"Curr Drug Metab"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"13768","DOI":"10.3390\/ijms150813768","volume":"15","author":"Hojjat-Farsangi M.","year":"2014","unstructured":"Hojjat-Farsangi M.; Small-molecule inhibitors of the receptor tyrosine kinases: Promising tools for targeted cancer therapies. Int J Mol Sci 2014,15(8),13768-13801","journal-title":"Int J Mol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.2174\/092986710791859333","volume":"17","author":"Garuti L.","year":"2010","unstructured":"Garuti L.; Roberti M.; Bottegoni G.; Non-ATP competitive protein kinase inhibitors. Curr Med Chem 2010,17(25),2804-2821","journal-title":"Curr Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/gb4184","volume":"15","author":"Malumbres M.","year":"2014","unstructured":"Malumbres M.; Cyclin-dependent kinases. Genome Biol 2014,15(6),122","journal-title":"Genome Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1158\/1535-7163.MCT-13-0263","volume":"12","author":"Haider C.","year":"2013","unstructured":"Haider C.; Grubinger M.; \u0158ezn\u00ed\u010dkov\u00e1 E.; Weiss T.S.; Rotheneder H.; Miklos W.; Berger W.; Jorda R.; Zatloukal M.; Guck\u00fd T.; Strnad M.; Kry\u0161tof V.; Mikulits W.; Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance. Mol Cancer Ther 2013,12(10),1947-1957","journal-title":"Mol Cancer Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrm2105","volume":"8","author":"Bloom J.","year":"2007","unstructured":"Bloom J.; Cross F.R.; Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol 2007,8(2),149-160","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/nm1468","volume":"12","author":"Rossi A.G.","year":"2006","unstructured":"Rossi A.G.; Sawatzky D.A.; Walker A.; Ward C.; Sheldrake T.A.; Riley N.A.; Caldicott A.; Martinez-Losa M.; Walker T.R.; Duffin R.; Gray M.; Crescenzi E.; Martin M.C.; Brady H.J.; Savill J.S.; Dransfield I.; Haslett C.; Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006,12(9),1056-1064","journal-title":"Nat Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/onc.2008.178","volume":"27","author":"Fornari F.","year":"2008","unstructured":"Fornari F.; Gramantieri L.; Ferracin M.; Veronese A.; Sabbioni S.; Calin G.A.; Grazi G.L.; Giovannini C.; Croce C.M.; Bolondi L.; Negrini M.; MiR-221 controls CDKN1C\/p57 and CDKN1B\/p27 expression in human hepatocellular carcinoma. Oncogene 2008,27(43),5651-5661","journal-title":"Oncogene"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.ceb.2004.09.014","volume":"16","author":"Senderowicz A.M.","year":"2004","unstructured":"Senderowicz A.M.; Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 2004,16(6),670-678","journal-title":"Curr Opin Cell Biol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/cancers6010079","volume":"6","author":"Bisteau X.","year":"2014","unstructured":"Bisteau X.; Caldez M.; Kaldis P.; The complex relationship between liver cancer and the cell cycle: A story of multiple regulations. Cancers 2014,6(1),79-111","journal-title":"Cancers"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/ncb1109-1275","volume":"11","author":"Malumbres M.","year":"2009","unstructured":"Malumbres M.; Harlow E.; Hunt T.; Hunter T.; Lahti J.M.; Manning G.; Morgan D.O.; Tsai L.H.; Wolgemuth D.J.; Cyclin-dependent kinases: A family portrait. Nat Cell Biol 2009,11(11),1275-1276","journal-title":"Nat Cell Biol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/978-3-642-19065-0_16","volume":"53","author":"Gopinathan L.","year":"2011","unstructured":"Gopinathan L.; Ratnacaram C.K.; Kaldis P.; Established and novel Cdk\/cyclin complexes regulating the cell cycle and development. Results Probl Cell Differ 2011,53,365-389","journal-title":"Results Probl Cell Differ"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e0143685","DOI":"10.1371\/journal.pone.0143685","volume":"10","author":"Paiva C.","year":"2015","unstructured":"Paiva C.; Godbersen J.C.; Soderquist R.S.; Rowland T.; Kilmarx S.; Spurgeon S.E.; Brown J.R.; Srinivasa S.P.; Danilov A.V.; Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK\/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells. PLoS One 2015,10(11),e0143685","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"7691","DOI":"10.18632\/oncotarget.2296","volume":"5","author":"Lam F.","year":"2014","unstructured":"Lam F.; Abbas A.Y.; Shao H.; Teo T.; Adams J.; Li P.; Bradshaw T.D.; Fischer P.M.; Walsby E.; Pepper C.; Chen Y.; Ding J.; Wang S.; Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget 2014,5(17),7691-7704","journal-title":"Oncotarget"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/bph.12408","volume":"171","author":"Albert T.K.","year":"2014","unstructured":"Albert T.K.; Rigault C.; Eickhoff J.; Baumgart K.; Antrecht C.; Klebl B.; Mittler G.; Meisterernst M.; Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J Pharmacol 2014,171(1),55-68","journal-title":"Br J Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1007\/s00018-013-1423-0","volume":"70","author":"Kitagawa M.","year":"2013","unstructured":"Kitagawa M.; Kitagawa K.; Kotake Y.; Niida H.; Ohhata T.; Cell cycle regulation by long non-coding RNAs. Cell Mol Life Sci 2013,70(24),4785-4794","journal-title":"Cell Mol Life Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/ijc.26127","volume":"130","author":"Liu X.","year":"2012","unstructured":"Liu X.; Shi S.; Lam F.; Pepper C.; Fischer P.M.; Wang S.; CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. Int J Cancer 2012,130(5),1216-1226","journal-title":"Int J Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s10637-011-9641-5","volume":"30","author":"Liu X.","year":"2012","unstructured":"Liu X.; Lam F.; Shi S.; Fischer P.M.; Wang S.; In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs 2012,30(3),889-897","journal-title":"Invest New Drugs"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.bjc.6605479","volume":"102","author":"Johnson N.","year":"2010","unstructured":"Johnson N.; Bentley J.; Wang L-Z.; Newell D.R.; Robson C.N.; Shapiro G.I.; Curtin N.J.; Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br J Cancer 2010,102(2),342-350","journal-title":"Br J Cancer"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-10-0190","volume":"9","author":"Albanese C.","year":"2010","unstructured":"Albanese C.; Alzani R.; Amboldi N.; Avanzi N.; Ballinari D.; Brasca M.G.; Festuccia C.; Fiorentini F.; Locatelli G.; Pastori W.; Patton V.; Roletto F.; Colotta F.; Galvani A.; Isacchi A.; Moll J.; Pesenti E.; Mercurio C.; Ciomei M.; Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther 2010,9(8),2243-2254","journal-title":"Mol Cancer Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","volume":"407","author":"Adnane L.","year":"2006","unstructured":"Adnane L.; Trail P.A.; Taylor I.; Wilhelm S.M.; Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol 2006,407,597-612","journal-title":"Methods Enzymol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","volume":"69","author":"Keating G.M.","year":"2009","unstructured":"Keating G.M.; Santoro A.; Sorafenib. Drugs 2009,69(2),223-240","journal-title":"Drugs"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/PPO.0b013e3181af5e35","volume":"15","author":"Zhu A.X.","year":"2009","unstructured":"Zhu A.X.; Duda D.G.; Sahani D.V.; Jain R.K.; Development of sunitinib in hepatocellular carcinoma: Rationale, early clinical experience, and correlative studies. Cancer J 2009,15(4),263-268","journal-title":"Cancer J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3892\/ol.2017.6177","volume":"14","author":"Liu T.","year":"2017","unstructured":"Liu T.; Liu R.; Zhang S.; Guo K.; Zhang Q.; Li W.; Liu Y.; Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells. Oncol Lett 2017,14(1),517-524","journal-title":"Oncol Lett"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4254\/wjh.v5.i7.345","volume":"5","author":"Zhai B.","year":"2013","unstructured":"Zhai B.; Sun X.Y.; Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013,5(7),345-352","journal-title":"World J Hepatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"Cheng A.L.","year":"2013","unstructured":"Cheng A.L.; Kang Y.K.; Lin D.Y.; Park J.W.; Kudo M.; Qin S.; Chung H.C.; Song X.; Xu J.; Poggi G.; Omata M.; Pitman L.S.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E.; Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 2013,31(32),4067-4075","journal-title":"J Clin Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","volume":"49","author":"Bruix J.","year":"2013","unstructured":"Bruix J.; Tak W.Y.; Gasbarrini A.; Santoro A.; Colombo M.; Lim H.Y.; Mazzaferro V.; Wiest R.; Reig M.; Wagner A.; Bolondi L.; Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. Eur J Cancer 2013,49(16),3412-3419","journal-title":"Eur J Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1158\/1078-0432.CCR-14-0725","volume":"20","author":"Tai W.T.","year":"2014","unstructured":"Tai W.T.; Chu P.Y.; Shiau C.W.; Chen Y.L.; Li Y.S.; Hung M.H.; Chen L.J.; Chen P.L.; Su J.C.; Lin P.Y.; Yu H.C.; Chen K.F.; STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. Clin Cancer Res 2014,20(22),5768-5776","journal-title":"Clin Cancer Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"Bruix J.","year":"2017","unstructured":"Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.P.; Ollivier-Hourmand I.; Kudo M.; Cheng A.L.; Llovet J.M.; Finn R.S.; LeBerre M.A.; Baumhauer A.; Meinhardt G.; Han G.; Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017,389(10064),56-66","journal-title":"Lancet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000449342","volume":"6","author":"Kudo M.","year":"2017","unstructured":"Kudo M.; Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer 2017,6(1),1-12","journal-title":"Liver Cancer"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"El-Khoueiry A.B.","year":"2017","unstructured":"El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; Hsu C.; Kim T.Y.; Choo S.P.; Trojan J.; Welling T.H.; Meyer T.; Kang Y.K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I.; Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017,389(10088),2492-2502","journal-title":"Lancet"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Yamamoto Y.","year":"2014","unstructured":"Yamamoto Y.; Matsui J.; Matsushima T.; Obaishi H.; Miyazaki K.; Nakamura K.; Tohyama O.; Semba T.; Yamaguchi A.; Hoshi S.; Mimura F.; Haneda T.; Fukuda Y.; Kamata J.; Takahashi K.; Matsukura M.; Wakabayashi T.; Asada M.; Nomoto K.; Watanabe T.; Dezso Z.; Yoshimatsu K.; Funahashi Y.; Tsuruoka A.; Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014,6(1),18","journal-title":"Vasc Cell"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"Ikeda K.","year":"2017","unstructured":"Ikeda K.; Kudo M.; Kawazoe S.; Osaki Y.; Ikeda M.; Okusaka T.; Tamai T.; Suzuki T.; Hisai T.; Hayato S.; Okita K.; Kumada H.; Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017,52(4),512-519","journal-title":"J Gastroenterol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cas.12581","volume":"106","author":"Nakazawa Y.","year":"2015","unstructured":"Nakazawa Y.; Kawano S.; Matsui J.; Funahashi Y.; Tohyama O.; Muto H.; Nakagawa T.; Matsushima T.; Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti\u2010angiogenesis activity in a preclinical cancer model. Cancer Sci 2015,106(2),201-207","journal-title":"Cancer Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.bulcan.2017.03.013","volume":"104","author":"Cochin V.","year":"2017","unstructured":"Cochin V.; Gross-Goupil M.; Ravaud A.; Godbert Y.; Le Moulec S.; Cabozantinib: Modalit\u00e9s d\u2019action, efficacit\u00e9 et indications. Bull Cancer 2017,104(5),393-401","journal-title":"Bull Cancer"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejca.2017.09.011","volume":"86","author":"Sch\u00f6ffski P.","year":"2017","unstructured":"Sch\u00f6ffski P.; Gordon M.; Smith D.C.; Kurzrock R.; Daud A.; Vogelzang N.J.; Lee Y.; Scheffold C.; Shapiro G.I.; Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer 2017,86,296-304","journal-title":"Eur J Cancer"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"Zhu A.X.","year":"2018","unstructured":"Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; Cheng A.L.; Kudo M.; Alistar A.; Asselah J.; Blanc J-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van V.H.; Weiss A.; Weiss K-H.; Yamashita T.; Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol 2018,19(7),940-952","journal-title":"Lancet Oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00535-016-1247-4","volume":"52","author":"Kudo M.","year":"2017","unstructured":"Kudo M.; Hatano E.; Ohkawa S.; Fujii H.; Masumoto A.; Furuse J.; Wada Y.; Ishii H.; Obi S.; Kaneko S.; Kawazoe S.; Yokosuka O.; Ikeda M.; Ukai K.; Morita S.; Tsuji A.; Kudo T.; Shimada M.; Osaki Y.; Tateishi R.; Sugiyama G.; Abada P.B.; Yang L.; Okusaka T.; Zhu A.X.; Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 2017,52(4),494-503","journal-title":"J Gastroenterol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-13-1442","volume":"19","author":"Zhu A.X.","year":"2013","unstructured":"Zhu A.X.; Finn R.S.; Mulcahy M.; Gurtler J.; Sun W.; Schwartz J.D.; Dalal R.P.; Joshi A.; Hozak R.R.; Xu Y.; Ancukiewicz M.; Jain R.K.; Nugent F.W.; Duda D.G.; Stuart K.; A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013,19(23),6614-6623","journal-title":"Clin Cancer Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"Herbst R.S.","year":"2014","unstructured":"Herbst R.S.; Soria J.C.; Kowanetz M.; Fine G.D.; Hamid O.; Gordon M.S.; Sosman J.A.; McDermott D.F.; Powderly J.D.; Gettinger S.N.; Kohrt H.E.K.; Horn L.; Lawrence D.P.; Rost S.; Leabman M.; Xiao Y.; Mokatrin A.; Koeppen H.; Hegde P.S.; Mellman I.; Chen D.S.; Hodi F.S.; Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014,515(7528),563-567","journal-title":"Nature"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","volume":"18","author":"Chen D.S.","year":"2012","unstructured":"Chen D.S.; Irving B.A.; Hodi F.S.; Molecular pathways: Next-generation immunotherapy inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012,18(24),6580-6587","journal-title":"Clin Cancer Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ni0702-611","volume":"3","author":"Egen J.G.","year":"2002","unstructured":"Egen J.G.; Kuhns M.S.; Allison J.P.; CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002,3(7),611-618","journal-title":"Nat Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00280-017-3303-z","volume":"79","author":"Aspeslagh S.","year":"2017","unstructured":"Aspeslagh S.; Shailubhai K.; Bahleda R.; Gazzah A.; Varga A.; Hollebecque A.; Massard C.; Spreafico A.; Reni M.; Soria J.C.; Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol 2017,79(6),1257-1265","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/1878-0261.12072","volume":"11","author":"Hsieh F.S.","year":"2017","unstructured":"Hsieh F.S.; Chen Y.L.; Hung M.H.; Chu P.Y.; Tsai M.H.; Chen L.J.; Hsiao Y.J.; Shih C.T.; Chang M.J.; Chao T.I.; Shiau C.W.; Chen K.F.; Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4\/6-independent manner. Mol Oncol 2017,11(8),1035-1049","journal-title":"Mol Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","volume":"66","author":"Bollard J.","year":"2017","unstructured":"Bollard J.; Miguela V.; Ruiz de Galarreta M.; Venkatesh A.; Bian C.B.; Roberto M.P.; Tovar V.; Sia D.; Molina-S\u00e1nchez P.; Nguyen C.B.; Nakagawa S.; Llovet J.M.; Hoshida Y.; Lujambio A.; Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 2017,66(7),1286-1296","journal-title":"Gut"},{"key":"ref=58","first-page":"4479","volume":"9","author":"Herbertz S.","year":"2015","unstructured":"Herbertz S.; Sawyer J.S.; Stauber A.J.; Gueorguieva I.; Driscoll K.E.; Estrem S.T.; Cleverly A.L.; Desaiah D.; Guba S.C.; Benhadji K.A.; Slapak C.A.; Lahn M.M.; Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015,9,4479-4499","journal-title":"Drug Des Devel Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccr.2010.10.023","volume":"18","author":"Anido J.","year":"2010","unstructured":"Anido J.; S\u00e1ez-Border\u00edas A.; Gonz\u00e0lez-Junc\u00e0 A.; Rod\u00f3n L.; Folch G.; Carmona M.A.; Prieto-S\u00e1nchez R.M.; Barba I.; Mart\u00ednez-S\u00e1ez E.; Prudkin L.; Cuartas I.; Ravent\u00f3s C.; Mart\u00ednez-Ricarte F.; Poca M.A.; Garc\u00eda-Dorado D.; Lahn M.M.; Yingling J.M.; Rod\u00f3n J.; Sahuquillo J.; Baselga J.; Seoane J.; TGF-beta receptor inhibitors target the CD44(high)\/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010,18(6),655-668","journal-title":"Cancer Cell"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ccr.2009.02.011","volume":"15","author":"Pe\u00f1uelas S.","year":"2009","unstructured":"Pe\u00f1uelas S.; Anido J.; Prieto-S\u00e1nchez R.M.; Folch G.; Barba I.; Cuartas I.; Garc\u00eda-Dorado D.; Poca M.A.; Sahuquillo J.; Baselga J.; Seoane J.; TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009,15(4),315-327","journal-title":"Cancer Cell"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1158\/0008-5472.CAN-12-0546","volume":"72","author":"Hardee M.E.","year":"2012","unstructured":"Hardee M.E.; Marciscano A.E.; Medina-Ramirez C.M.; Zagzag D.; Narayana A.; Lonning S.M.; Barcellos-Hoff M.H.; Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-\u03b2. Cancer Res 2012,72(16),4119-4129","journal-title":"Cancer Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.08.005","volume":"146","author":"Le P.N.","year":"2015","unstructured":"Le P.N.; McDermott J.D.; Jimeno A.; Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 2015,146,1-11","journal-title":"Pharmacol Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","volume":"23","author":"Jimeno A.","year":"2017","unstructured":"Jimeno A.; Gordon M.; Chugh R.; Messersmith W.; Mendelson D.; Dupont J.; Stagg R.; Kapoun A.M.; Xu L.; Uttamsingh S.; Brachmann R.K.; Smith D.C.; A first-in-human Phase 1 study of the anti-cancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin Cancer Res 2017,23(24),7490-7497","journal-title":"Clin Cancer Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"Johnson P.J.","year":"2013","unstructured":"Johnson P.J.; Qin S.; Park J.W.; Poon R.T.P.; Raoul J.L.; Philip P.A.; Hsu C.H.; Hu T.H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.H.; Paik S.W.; Robles-Avi\u00f1a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.Y.; Jeng L.B.; Liu D.; Ezzeddine R.; Walters I.; Cheng A.L.; Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 2013,31(28),3517-3524","journal-title":"J Clin Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","volume":"31","author":"Llovet J.M.","year":"2013","unstructured":"Llovet J.M.; Decaens T.; Raoul J.L.; Boucher E.; Kudo M.; Chang C.; Kang Y.K.; Assenat E.; Lim H.Y.; Boige V.; Mathurin P.; Fartoux L.; Lin D.Y.; Bruix J.; Poon R.T.; Sherman M.; Blanc J.F.; Finn R.S.; Tak W.Y.; Chao Y.; Ezzeddine R.; Liu D.; Walters I.; Park J.W.; Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J Clin Oncol 2013,31(28),3509-3516","journal-title":"J Clin Oncol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/hep.27290","volume":"60","author":"Kudo M.","year":"2014","unstructured":"Kudo M.; Han G.; Finn R.S.; Poon R.T.P.; Blanc J.F.; Yan L.; Yang J.; Lu L.; Tak W.Y.; Yu X.; Lee J.H.; Lin S.M.; Wu C.; Tanwandee T.; Shao G.; Walters I.B.; Dela Cruz C.; Poulart V.; Wang J.H.; Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology 2014,60(5),1697-1707","journal-title":"Hepatology"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","volume":"33","author":"Cainap C.","year":"2015","unstructured":"Cainap C.; Qin S.; Huang W.T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.K.; Chen P.J.; Toh H.C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S.; Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 2015,33(2),172-179","journal-title":"J Clin Oncol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ejmech.2014.06.060","volume":"83","author":"Yoon Y.K.","year":"2014","unstructured":"Yoon Y.K.; Ali M.A.; Wei A.C.; Shirazi A.N.; Parang K.; Choon T.S.; Benzimidazoles as new scaffold of sirtuin inhibitors: Green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties. Eur J Med Chem 2014,83,448-454","journal-title":"Eur J Med Chem"},{"key":"ref=69","first-page":"4109","volume":"8","author":"Rawat S.","year":"2021","unstructured":"Rawat S.; Ghate M.; Potential anticancer agents from benzimidazole derivatives. Nat Volatiles Essent Oils 2021,8(6),4109-4120","journal-title":"Nat Volatiles Essent Oils"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.bmc.2015.02.036","volume":"23","author":"Gao C.","year":"2015","unstructured":"Gao C.; Li B.; Zhang B.; Sun Q.; Li L.; Li X.; Chen C.; Tan C.; Liu H.; Jiang Y.; Synthesis and biological evaluation of benzimidazole acridine derivatives as potential DNA-binding and apoptosis-inducing agents. Bioorg Med Chem 2015,23(8),1800-1807","journal-title":"Bioorg Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1016\/j.bmcl.2014.06.050","volume":"24","author":"Shao K.P.","year":"2014","unstructured":"Shao K.P.; Zhang X.Y.; Chen P.J.; Xue D.Q.; He P.; Ma L.Y.; Zheng J.X.; Zhang Q.R.; Liu H.M.; Synthesis and biological evaluation of novel pyrimidine\u2013benzimidazol hybrids as potential anticancer agents. Bioorg Med Chem Lett 2014,24(16),3877-3881","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ejmech.2010.11.014","volume":"46","author":"Luo Y.","year":"2011","unstructured":"Luo Y.; Xiao F.; Qian S.; Lu W.; Yang B.; Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives. Eur J Med Chem 2011,46(1),417-422","journal-title":"Eur J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejmech.2019.06.054","volume":"179","author":"Yuan X.","year":"2019","unstructured":"Yuan X.; Yang Q.; Liu T.; Li K.; Liu Y.; Zhu C.; Zhang Z.; Li L.; Zhang C.; Xie M.; Lin J.; Zhang J.; Jin Y.; Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole\/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase. Eur J Med Chem 2019,179,147-165","journal-title":"Eur J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.ejmech.2009.12.024","volume":"45","author":"Kumar D.","year":"2010","unstructured":"Kumar D.; Kumar N.M.; Sundaree S.; Johnson E.O.; Shah K.; An expeditious synthesis and anticancer activity of novel 4-(3\u2032-indolyl)oxazoles. Eur J Med Chem 2010,45(3),1244-1249","journal-title":"Eur J Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.bmcl.2014.03.011","volume":"24","author":"Ke S.","year":"2014","unstructured":"Ke S.; Yang Z.; Zhang Z.; Liang Y.; Wang K.; Liu M.; Shi L.; Multisubstituted indole\u2013acrylonitrile hybrids as potential cytotoxic agents. Bioorg Med Chem Lett 2014,24(8),1907-1911","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/ijms19082232","volume":"19","author":"Mphahlele M.J.","year":"2018","unstructured":"Mphahlele M.J.; Mmakwena M.M.; Abimbola A.; Synthesis, biological evaluation and molecular docking of novel indole-aminoquinazoline hybrids for anticancer properties. Int J Mol Sci 2018,19(8),2232","journal-title":"Int J Mol Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13065-021-00793-8","volume":"15","author":"Hawash M.","year":"2021","unstructured":"Hawash M.; Kahraman D.C.; Ergun S.G.; Atalay R.C.; Synthesis of novel indole - isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines. BMC Chem 2021,15(1),66","journal-title":"BMC Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/adsc.201500319","volume":"357","author":"Hu F.","year":"2015","unstructured":"Hu F.; Szostak M.; Recent developments in the synthesis and reactivity of isoxazoles: Metal catalysis and beyond. Adv Synth Catal 2015,357(12),2583-2614","journal-title":"Adv Synth Catal"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"113489","DOI":"10.1016\/j.ejmech.2021.113489","volume":"221","author":"\u0130bi\u015f K.","year":"2021","unstructured":"\u0130bi\u015f K.; Nalbat E.; \u00c7al\u0131\u015fkan B.; Kahraman D.C.; Cetin-Atalay R.; Banoglu E.; Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells. Eur J Med Chem 2021,221,113489","journal-title":"Eur J Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ejmech.2012.06.001","volume":"54","author":"Shi L.","year":"2012","unstructured":"Shi L.; Hu R.; Wei Y.; Liang Y.; Yang Z.; Ke S.; Anthranilic acid-based diamides derivatives incorporating aryl-isoxazoline pharmacophore as potential anticancer agents: Design, synthesis and biological evaluation. Eur J Med Chem 2012,54,549-556","journal-title":"Eur J Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11030-020-10050-0","volume":"25","author":"Ghanaat J.","year":"2021","unstructured":"Ghanaat J.; Khalilzadeh M.A.; Zareyee D.; Molecular docking studies, biological evaluation and synthesis of novel 3-mercapto-1,2,4-triazole derivatives. Mol Divers 2021,25(1),223-232","journal-title":"Mol Divers"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.bmc.2013.02.008","volume":"21","author":"Du Q.R.","year":"2013","unstructured":"Du Q.R.; Li D.D.; Pi Y.Z.; Li J.R.; Sun J.; Fang F.; Zhong W.Q.; Gong H.B.; Zhu H.L.; Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer\/antimicrobial agents. Bioorg Med Chem 2013,21(8),2286-2297","journal-title":"Bioorg Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/jhet.3110","volume":"55","author":"Madhavilatha B.","year":"2018","unstructured":"Madhavilatha B.; Bhattacharjee D.; Sabitha G.; Reddy B.V.S.; Yadav J.S.; Jain N.; Reddy B.J.M.; Synthesis and in vitro anticancer activity of novel 1,3,4-oxadiazole-linked 1,2,3-Triazole\/Isoxazole hybrids. J Heterocycl Chem 2018,55(4),863-870","journal-title":"J Heterocycl Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ejmech.2013.03.008","volume":"63","author":"Arafa R.K.","year":"2013","unstructured":"Arafa R.K.; Hegazy G.H.; Piazza G.A.; Abadi A.H.; Synthesis and in vitro antiproliferative effect of novel quinoline-based potential anticancer agents. Eur J Med Chem 2013,63,826-832","journal-title":"Eur J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejmech.2013.04.001","volume":"64","author":"Li S.","year":"2013","unstructured":"Li S.; Huang Q.; Liu Y.; Zhang X.; Liu S.; He C.; Gong P.; Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety. Eur J Med Chem 2013,64,62-73","journal-title":"Eur J Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.saa.2014.06.145","volume":"135","author":"Helal M.H.","year":"2015","unstructured":"Helal M.H.; El-Awdan S.A.; Salem M.A.; Abd-elaziz T.A.; Moahamed Y.A.; El-Sherif A.A.; Mohamed G.A.M.; Synthesis, biological evaluation and molecular modeling of novel series of pyridine derivatives as anticancer, anti-inflammatory and analgesic agents. Spectrochim Acta A Mol Biomol Spectrosc 2015,135,764-773","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ejmech.2013.04.008","volume":"64","author":"Chen T.","year":"2013","unstructured":"Chen T.; Luo Y.; Hu Y.; Yang B.; Lu W.; Synthesis and biological evaluation of novel 1,6-diaryl pyridin-2(1H)-one analogs. Eur J Med Chem 2013,64,613-620","journal-title":"Eur J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/14756366.2019.1612889","volume":"34","author":"Ahmed N.M.","year":"2019","unstructured":"Ahmed N.M.; Youns M.; Soltan M.K.; Said A.M.; Design, synthesis, molecular modelling, and biological evaluation of novel substituted pyrimidine derivatives as potential anticancer agents for hepatocellular carcinoma. J Enzyme Inhib Med Chem 2019,34(1),1110-1120","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ejmech.2009.10.042","volume":"45","author":"Sondhi S.M.","year":"2010","unstructured":"Sondhi S.M.; Singh J.; Rani R.; Gupta P.P.; Agrawal S.K.; Saxena A.K.; Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives. Eur J Med Chem 2010,45(2),555-563","journal-title":"Eur J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1016\/j.bmc.2013.05.008","volume":"21","author":"Lang X.","year":"2013","unstructured":"Lang X.; Li L.; Chen Y.; Sun Q.; Wu Q.; Liu F.; Tan C.; Liu H.; Gao C.; Jiang Y.; Novel synthetic acridine derivatives as potent DNA-binding and apoptosis-inducing antitumor agents. Bioorg Med Chem 2013,21(14),4170-4177","journal-title":"Bioorg Med Chem"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557523666230508160924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216680\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557523666230508160924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:20:37Z","timestamp":1697631637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216680\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":90,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557523666230508160924","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}